Compare MRBK & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRBK | SGMO |
|---|---|---|
| Founded | 2004 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 155.1M |
| IPO Year | 2017 | 2000 |
| Metric | MRBK | SGMO |
|---|---|---|
| Price | $17.24 | $0.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $18.00 | $4.71 |
| AVG Volume (30 Days) | 80.2K | ★ 9.2M |
| Earning Date | 01-23-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 75.95 | N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | ★ $109,758,000.00 | $32,875,000.00 |
| Revenue This Year | $26.84 | $1.37 |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | $9.75 | ★ N/A |
| Revenue Growth | ★ 18.84 | N/A |
| 52 Week Low | $11.16 | $0.38 |
| 52 Week High | $17.43 | $2.84 |
| Indicator | MRBK | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 77.07 | 43.51 |
| Support Level | $16.25 | $0.49 |
| Resistance Level | $16.59 | $0.51 |
| Average True Range (ATR) | 0.33 | 0.04 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 91.70 | 31.04 |
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.